Clinical trial NCT00659282 - References

Diabetes Mellitus, Type 2 — Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes

Citation(s)

•   Gumprecht J, Benroubi M, Borzi V, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, Ligthelm R, Valensi P; IMPROVE Study Group Expert Panel
  Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in pati
•   Ishii H, Iwase M, Seino H, Shuto Y, Atsumi Y
  Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan. Curr Med Res Opin. 2011 Mar;27(3):643-50
•   Shah S, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shestakova M, Wenying Y, Valensi P; IMPROVE Study Group Expert Panel
  Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patien
•   Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y; IMPROVE Study Group Expert Panel
  Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in
•   Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y; IMPROVE Study Group Expert Panel
  The IMPROVE study--a multinational, observational study in type 2 diabetes: baseline characteristics from eight national
•   Valensi P, Husemoen LLN, Weatherall J, Monnier L
  Association of postprandial and fasting plasma glucose with HbA1c across the spectrum of glycaemic impairment in type 2 diabetes. Int J Clin Pract. 2017 Dec;71(12). doi: 10.1111/ijcp.13041.
•   Valensi P, Shaban J, Benroubi M, Kawamori R, Borzì V, Shah S, Wenying Y, Prusty V, Hansen JB, Gumprecht J; IMPROVE Study Expert Panel
  Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in pati
•   Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P; IMPROVE Study Group Expert Panel
  Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on
•   Yang W, Gao Y, Liu G, Chen L, Fu Z, Zou D, Feng P, Zhao Z
  Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study. Curr Med Res Opin. 2010 Jan;26(1):101-7. doi: 10.1185/03007990903364640.

Observational Study of Safety and Effectiveness of NovoMix® 30 (Biphasic Insulin Aspart) for the Treatment of Diabetes Mellitus

Details for clinical trial NCT00659282